Treatment of idiopathic granulomatous mastitis: a retrospective case series
Rheumatology International · 2025
DOI: 10.1007/s00296-024-05773-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Rheumatology International, 2025. Verfasst von Aurélie Mourot und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Centre hospitalier de l'Université de Montréal (CHUM), Department of Medicine, Université de Montréal, Montreal, Canada. au…. Hauptthemen laut MEDLINE: Granulomatous Mastitis, Anti-Bacterial Agents, Antirheumatic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
Idiopathic granulomatous mastitis (IGM) is a rare inflammatory disease of the breast. Various clinical management approaches have been described, but their efficacy and optimal sequential order remain uncertain. We describe the first Canadian cohort of patients with IGM, discuss treatment outcomes and outline a practical management approach. This retrospective study included patients diagnosed with biopsy-confirmed IGM between 2014 and 2023, aged over 18 years. Based on a scoping review of the literature, a diagnostic and management approach was developed, and we present here the disease course and outcomes using this approach. 22 females were included, with a mean age of 40 (24-65) years, mostly presenting with a breast lump (n =22, 100%) and breast pain (n = 15, 68%). Mean rheumatology follow-up was 28.7 months (range 3-79). Mean time from first symptom to diagnosis was 3.5 months (range 1-13). Corynebacterium kroppenstedtii was found in 8 patients. Treatment including lipophilic antibiotics, corticosteroids and disease modifying anti-rheumatic drugs (DMARDs), led to complete remission in 95% of patients, in a mean time of 11.6 months (range 1-36), and relapse in only 1 patient. 11 patients required DMARDs (50%), most commonly methotrexate (n=9). We highlight the variable severity of IGM and the benefits of a severity-based treatment approach. A diligent evaluation and work-up is essential to manage IGM. The proposed severity-based management approach with medical treatment and less aggressive surgical intervention led to complete remission in 95%.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Centre hospitalier de l'Université de Montréal (CHUM), Department of Medicine, Université de Montréal, Montreal, Canada. aurelie.mourot@umontreal.ca.
- Division of Rheumatology, Centre hospitalier de l'Université de Montréal (CHUM), Department of Medicine, Université de Montréal, Montreal, Canada.
- Department of Microbiology, Immunology and Infectious Diseases, Université de Montréal, Montreal, Canada.
- Immunopathology Axis, Centre de Recherche du Centre hospitalier de l'Université de Montréal, Montreal, Canada.
- Division of Surgical Oncology, Department of Surgery, CHUM, Université de Montréal, Montreal, Canada.
- Cancer Axis, Centre de Recherche du Centre hospitalier de l'Université de Montréal, Montreal, Canada.
ORCID-Profile: Aurélie Mourot, Simon Grandjean-Lapierre
Zitieren
APA
Mourot, A., Chalut, M., Grandjean-Lapierre, S., Younan, R., & Bourré-Tessier, J. (2025). Treatment of idiopathic granulomatous mastitis: a retrospective case series. Rheumatology International. https://doi.org/10.1007/s00296-024-05773-4
Vancouver
Mourot A, Chalut M, Grandjean-Lapierre S, Younan R, Bourré-Tessier J. Treatment of idiopathic granulomatous mastitis: a retrospective case series. Rheumatology International. 2025. doi:10.1007/s00296-024-05773-4
BibTeX
@article{Mourot2025,
author = {Mourot, Aurélie and Chalut, Marianne and Grandjean-Lapierre, Simon and Younan, Rami and Bourré-Tessier, Josiane},
title = {Treatment of idiopathic granulomatous mastitis: a retrospective case series},
journal = {Rheumatology International},
year = {2025},
doi = {10.1007/s00296-024-05773-4}
}
EUVIMED